Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin
about
Kinetics methods for clinical epidemiology problemsAsian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral AnticoagulantsStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Re-initiation of dabigatran and direct factor Xa antagonists after a major bleedShould oral anticoagulant therapy be continued during dental extraction? A meta-analysisAnticoagulation in atrial fibrillationImpact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patientsPersonalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry.Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.Intersection of cardiovascular disease and kidney disease: atrial fibrillation.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation?Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failureRisk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis.Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry.Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillationProteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort Study.Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation.Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients.Elevated Blood Urea Nitrogen is Associated With Critical Limb Ischemia in Peripheral Arterial Disease PatientsRenal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs re-expressed 4 variable modification of diet in renal disease.Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatmentStroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events.Predicting Atrial Fibrillation and Its Complications.Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF TrialsStroke Risk Predictor Scoring Systems in Atrial Fibrillation.Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan.CHA2DS2-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillationRisk of Ischemic Stroke and Stroke Prevention in Patients with Atrial Fibrillation and Renal Dysfunction.
P2860
Q24289246-87A1FB21-BECD-496D-B8E2-8AFC3B8C55DAQ26750467-8503631E-F295-4F0B-B511-F2D324FB65C2Q26781181-29602D0C-4178-436E-AA8C-7BFD2C82E4EDQ27341873-CE5F278F-1EF5-4F84-BA1F-7CAB69F4AB20Q28067358-8C8EC294-796A-4C2B-A1FB-244BBA656F58Q28278099-5019617C-4ABF-4AAC-86F7-AF350260C6B9Q28315636-802823A1-5819-4B11-BD31-3B18A251AC25Q28541044-FF8D5DC5-A505-4142-B592-03FD947C1538Q30663685-FB7CF722-AA9B-483F-9697-9F472C8A70A4Q33427274-676C6A22-868F-42A8-A83B-E7CA4B955BA4Q33720574-AE7B98CD-EE46-462A-B406-20D1A4E23053Q33844478-A309B272-9788-429F-9755-EAB7C617964FQ33911981-DC6EAD45-C6C5-4301-BB29-201D9592F518Q34040279-A0E5AB42-C949-4547-8FEB-3DEE1845BDC6Q34651036-5B27BF0F-1E3B-4A9D-AB10-2BB4DC84F9A4Q34651051-EB0453CB-C11D-41EE-A56F-B3624DFB6D60Q34725585-1C2709DC-2426-426D-A6C5-B65D86E89F9EQ34768331-2AC705B4-2CF6-4ACC-84F3-26D719AC3E74Q35026442-0833FD40-3553-4986-B43A-32FDFF82C141Q35036404-5A5ECA0E-AC29-4FC2-BC6B-CFC824E9E6D8Q35062021-C0042162-4160-4CC8-9F48-29F52866A6C0Q35062047-FD9E8C65-0492-4F1C-8A52-F48CFB46073FQ35207851-31B2108E-2413-433A-AC59-19D11080A214Q35640960-DFBE137A-A323-47EF-A2BB-60A5ED8673E7Q35806598-E17241D9-B333-47A2-9470-7CA244022310Q35833389-2B76953F-2F42-49E5-A99D-1D624A887245Q35846377-230A2114-00B9-41B1-9FA9-5E94A239E2F4Q35901161-747B6D0E-F7B8-41FF-ACF8-8026126BC3ECQ36146288-0A0199A8-7517-478D-8AC2-19958D09CAD7Q36168690-02495C7E-D68E-4217-8F4E-A3BE8FEC0D4CQ36194559-357E7E3C-F529-41AC-8EEC-7DA2DA69923FQ36204885-10917E1C-4898-4C5A-B54E-31A93610055BQ36411967-6DF7B7DE-49E8-41EB-A7F1-2809011A71B0Q36458873-3D995108-840A-4163-A91A-4B414712C7DDQ37020619-4BEB1050-0211-4D78-B165-F33D195EFD4EQ37035168-190F1435-CF98-4199-B562-49A4B479306DQ37115147-91619E92-E225-4F79-9D57-FA3649E5E0B3Q37205144-9698946E-D12C-41B6-86D7-59C405FE1C6CQ37239448-0780E789-783D-4C54-8F97-CC87966B2C29Q37468787-809B1F98-A036-4365-907E-401573A0A10E
P2860
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Renal dysfunction as a predict ...... hibition Compared with vitamin
@en
type
label
Renal dysfunction as a predict ...... hibition Compared with vitamin
@en
prefLabel
Renal dysfunction as a predict ...... hibition Compared with vitamin
@en
P2093
P50
P921
P1433
P1476
Renal dysfunction as a predict ...... hibition Compared with vitamin
@en
P2093
Christopher C Nessel
Daniel E Singer
Keith A A Fox
Manesh R Patel
ROCKET AF Steering Committee and Investigators
Richard C Becker
Susanna R Stevens
Werner Hacke
YuChiao Chang
P304
P356
10.1161/CIRCULATIONAHA.112.107128
P407
P50
P577
2012-12-03T00:00:00Z